| __timestamp | Exelixis, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 5078000000 |
| Thursday, January 1, 2015 | 57305000 | 4717000000 |
| Friday, January 1, 2016 | 116145000 | 5096000000 |
| Sunday, January 1, 2017 | 159362000 | 4986000000 |
| Monday, January 1, 2018 | 206366000 | 4214000000 |
| Tuesday, January 1, 2019 | 228244000 | 3806000000 |
| Wednesday, January 1, 2020 | 293355000 | 3671000000 |
| Friday, January 1, 2021 | 401715000 | 3528000000 |
| Saturday, January 1, 2022 | 459856000 | 3445000000 |
| Sunday, January 1, 2023 | 542705000 | 3498000000 |
| Monday, January 1, 2024 | 492128000 | 3702000000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Exelixis, Inc. from 2014 to 2023. Over this period, Teva consistently reported higher SG&A expenses, peaking in 2016 with approximately $5.1 billion. However, a notable decline of about 32% was observed by 2023, reflecting strategic cost management. In contrast, Exelixis, Inc. demonstrated a steady increase in SG&A expenses, growing nearly tenfold from 2014 to 2023, reaching around $543 million. This growth aligns with Exelixis's expansion and increased market presence. The contrasting trends highlight Teva's focus on cost reduction and Exelixis's investment in growth. These insights provide a window into the strategic priorities of each company, offering valuable lessons in balancing cost efficiency with growth ambitions.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Exelixis, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.